Vigil
Vigil is a biological therapy with 11 clinical trials. Currently 1 active trials ongoing. Historical success rate of 87.5%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
6
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
77.8%
7 of 9 finished
22.2%
2 ended early
1
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Trial of Vigil for Participants With Ovarian Cancer
A Trial of FANG™ Vaccine for Participants With Ovarian Cancer
Expanded Access of Vigil in Solid Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Clinical Trials (11)
A Trial of Vigil for Participants With Ovarian Cancer
A Trial of FANG™ Vaccine for Participants With Ovarian Cancer
Expanded Access of Vigil in Solid Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.
All 11 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 11